DiaMedica Appoints Lorianne Masuoka As Chief Medical Officer
(RTTNews) - Biopharmaceutical company DiaMedica Therapeutics Inc. (DMAC) announced Monday the appointment of Lorianne Masuoka as Chief Medical Officer. Masuoka is a board-certified neurologist with more than 25 years of experience in managing clinical programs from early stage to drug approvals and strategic alliances.
Masuoka is a board-certified neurologist, experienced in treating stroke patients, who has successfully created and overseen high performing teams to lead the clinical development of new medicines, with a focus in neurology and oncology.
Masuoka served as Chief Medical Officer of Epygenix Therapeutics, Marinus Pharmaceuticals (MRNS), Cubist Pharmaceuticals, and Nektar Therapeutics (NKTR) where she managed teams in the areas of clinical research, pharmacovigilance, biostatistics and data management, regulatory affairs, and clinical operations.
Previously, she held various roles of increasing responsibility at FivePrime Therapeutics and Chiron (now Novartis). In addition to her executive roles, Masuoka most recently served as a Board member at Pfenex Inc. and serves as a Board member at Opiant Pharmaceuticals.
In connection with Masuoka's appointment, DiaMedica granted her an inducement stock option to purchase 285,000 shares of DiaMedica's common stock pursuant to the DiaMedica Therapeutics, Inc. 2021 Employment Inducement Incentive Plan.
DiaMedica Therapeutics Says FDA Lifts Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke
Australian Dollar Rises Against Majors
European Shares Seen Mostly Lower Before US Inflation Data
Sensex, Nifty Struggle For Direction In Early Trade
Australian Market Swings To Modest Gains In Mid-market
Asian Markets Mixed Amid Caution Trades
Sensex, Nifty Seen Tad Higher At Open As IIP Growth Recovers
